These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34849724)
1. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. de Boer LM; Oorthuys AOJ; Wiegman A; Langendam MW; Kroon J; Spijker R; Zwinderman AH; Hutten BA Eur J Prev Cardiol; 2022 May; 29(5):779-792. PubMed ID: 34849724 [TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. Hodkinson A; Tsimpida D; Kontopantelis E; Rutter MK; Mamas MA; Panagioti M BMJ; 2022 Mar; 376():e067731. PubMed ID: 35331984 [TBL] [Abstract][Full Text] [Related]
3. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. Byrne P; Demasi M; Jones M; Smith SM; O'Brien KK; DuBroff R JAMA Intern Med; 2022 May; 182(5):474-481. PubMed ID: 35285850 [TBL] [Abstract][Full Text] [Related]
4. Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. Yanai H; Adachi H; Hakoshima M; Katsuyama H Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362288 [TBL] [Abstract][Full Text] [Related]
5. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854 [TBL] [Abstract][Full Text] [Related]
6. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Willeit P; Ridker PM; Nestel PJ; Simes J; Tonkin AM; Pedersen TR; Schwartz GG; Olsson AG; Colhoun HM; Kronenberg F; Drechsler C; Wanner C; Mora S; Lesogor A; Tsimikas S Lancet; 2018 Oct; 392(10155):1311-1320. PubMed ID: 30293769 [TBL] [Abstract][Full Text] [Related]
8. Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis. Lee DY; Huang CJ; Yeh WY; Sung SH; Chen CH; Cheng HM J Chin Med Assoc; 2023 Feb; 86(2):155-165. PubMed ID: 36652565 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441 [TBL] [Abstract][Full Text] [Related]
10. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: A network meta-analysis. Wang X; Li J; Ju J; Fan Y; Xu H Pharmacol Res; 2021 Jan; 163():105275. PubMed ID: 33166736 [TBL] [Abstract][Full Text] [Related]
11. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. Sahebkar A; Simental-Mendía LE; Watts GF; Serban MC; Banach M; BMC Med; 2017 Feb; 15(1):22. PubMed ID: 28153024 [TBL] [Abstract][Full Text] [Related]
14. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Yu M; Liang C; Kong Q; Wang Y; Li M Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179 [TBL] [Abstract][Full Text] [Related]